Submit Deal

CROSSBOW THERAPEUTICS

Summary

Crossbow Therapeutics is a biotechnology company developing a novel class of potent and precise antibody therapies to treat a broad range of cancers.

Deals Overview

Total Deals1

Valued Deals1

Total Value£ 62 M

Avg. Deal Size£ 62 M

Market Context

Senior Management

Briggs Morrison
CEO
Geraldine Paulus
Co-Founder & Vice President of Corporate Development and Operations

Sort

Target: CROSSBOW THERAPEUTICS

Bidder: MIRAE ASSET VENTURE INVESTMENT

8 Service Providers

9 Dealmakers

£ 62 M

Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy